ReviewInternational journal of molecular sciences2017
Melatonin and Fertoprotective Adjuvants: Prevention against Premature Ovarian Failure during Chemotherapy.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Mouse Bone Mesenchymal Stem Cells Attenuate Apoptosis by Regulating the Bcl2/Caspase3 Signaling Pathway in Premature Ovarian Failure.Reproductive sciences (Thousand Oaks, Calif.) · 2026Article
- Molecular mechanisms underlying cyclophosphamide-induced ovarian injury and protective strategies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Investigation of the Efficacy of Umbilical Cord Mesenchymal Stem Cell and Melatonin Treatment in Premature Ovarian Failure Model.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Secretome from estrogen-responding human placenta-derived mesenchymal stem cells rescues ovarian function and circadian rhythm in mice with cyclophosphamide-induced primary ovarian insufficiency.Journal of biomedical science · 2024Article
- Review
- Antioxidant therapy for infertile couples: a comprehensive review of the current status and consideration of future prospects.Frontiers in endocrinology · 2024Review
- Premature ovarian insufficiency: a review on the role of oxidative stress and the application of antioxidants.Frontiers in endocrinology · 2023Review
- Application of Nanoparticles and Melatonin for Cryopreservation of Gametes and Embryos.Current issues in molecular biology · 2022Review
- Melatonin Alleviates Oxidative Stress Induced by HAntioxidants (Basel, Switzerland) · 2022Article
- Beneficial Effects of Traditional Chinese Medicine in the Treatment of Premature Ovarian Failure.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Melatonin prevents cyclophosphamide-induced primordial follicle loss by inhibiting ovarian granulosa cell apoptosis and maintaining AMH expression.Frontiers in endocrinology · 2022Article
- Female Oncofertility: Current Understandings, Therapeutic Approaches, Controversies, and Future Perspectives.Journal of clinical medicine · 2021Review
- Sphingosine-1-phosphate and its mimetic FTY720 do not protect against radiation-induced ovarian fibrosis in the nonhuman primate†.Biology of reproduction · 2021Article
- The Treatment of Complementary and Alternative Medicine on Premature Ovarian Failure.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- The Therapeutic Effect of Stem Cells on Chemotherapy-Induced Premature Ovarian Failure.Current molecular medicine · 2021Review
- Melatonin Inhibits Oxidative Stress and Apoptosis in Cryopreserved Ovarian Tissues via Nrf2/HO-1 Signaling Pathway.Frontiers in molecular biosciences · 2020Article
- The Impact of Chemotherapy on the Ovaries: Molecular Aspects and the Prevention of Ovarian Damage.International journal of molecular sciences · 2019Review
- Melatonin is a potential inhibitor of ovarian cancer: molecular aspects.Journal of ovarian research · 2019Review
- Fertility preservation in ovarian tumours.Ecancermedicalscience · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Premature ovarian failure is one of the side effects of chemotherapy in pre-menopausal cancer patients. Preservation of fertility has become increasingly important in improving the quality of life of completely recovered cancer patients. Among the possible strategies for preserving fertility such as ovarian tissue cryopreservation, co-treatment with a pharmacological adjuvant is highly effective and poses less of a burden on the human body. Melatonin is generally produced in various tissues and acts as a universally acting antioxidant in cells. Melatonin is now more widely used in various biological processes including treating insomnia and an adjuvant during chemotherapy. In this review, we summarize the information indicating that melatonin may be useful for reducing and preventing premature ovarian failure in chemotherapy-treated female patients. We also mention that many adjuvants other than melatonin are developed and used to inhibit chemotherapy-induced infertility. This information will give us novel insights on the clinical use of melatonin and other agents as fertoprotective adjuvants for female cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.